Parameters | N (%) | PNI | P value | |
---|---|---|---|---|
< 45.45 N (%) | ≥ 45.45 N (%) | |||
Age | ||||
< 56 | 423 (48.8%) | 181 (45.9%) | 242 (51.3%) | 0.133 |
≥ 56 | 443 (51.2%) | 213 (54.1%) | 230 (48.7%) | |
FIGO stage | ||||
Early (I, II) | 75 (8.7%) | 18 (4.6%) | 57 (12.1%) | < 0.001 |
Advanced (III, IV) | 791 (91.3%) | 376 (95.4%) | 415 (87.9%) | |
CA125 | ||||
< 500 | 190 (22.5%) | 65 (16.9%) | 125 (27.1%) | < 0.001 |
≥ 500 | 656 (77.5%) | 319 (83.1%) | 337 (72.9%) | |
Ascites | ||||
No | 99 (11.4%) | 14 (3.6%) | 85 (18.0%) | < 0.001 |
< 500 | 144 (16.6%) | 27 (6.9%) | 117 (24.8%) | |
≥ 500 | 622 (71.9%) | 353 (89.6%) | 269 (57.1%) | |
Residual disease | ||||
No | 270 (31.2%) | 77 (19.5%) | 193 (40.9%) | < 0.001 |
Yes | 596 (68.8%) | 317 (80.5%) | 279 (59.1%) | |
Platinum sensitivity | ||||
Yes | 561 (70.5%) | 223 (62.8%) | 338 (76.6%) | < 0.001 |
No | 235 (29.5%) | 132 (37.2%) | 103 (23.4%) | |
BMI | ||||
Underweight (< 18.5) | 47 (5.5%) | 27 (7.0%) | 20 (4.3%) | 0.023 |
Normal (18.5–23.9) | 591 (69.8%) | 250 (64.8%) | 341 (74.0%) | |
Overweight (24–27.9) | 184 (21.7%) | 94 (24.4%) | 90 (19.5%) | |
Obese (≥ 28) | 25 (3.0%) | 15 (3.9%) | 10 (2.2%) |